Bagvaerd, Denmark – Employees of Novo Nordisk A/S elected employee representatives to the Board of Directors of Novo Nordisk A/S.
Were elected for the next four years:
Elisabeth Dahl Christensen (newly elected), Liselotte Hyveled (newly elected), Mette Bojer Jensen (reelected), Thomas Rantzau (re-elected)
In replacement of the directors elected by the employees, were elected: Anders Kaae, Karina Bonde-Lenau, Jesper Thorning, Tanja Villamsen
The new directors elected by the employees will join the board of directors at the end of the annual general meeting of Novo Nordisk A/S to March 24, 2022. At the same time, current board members Anne-Marie Kvernelandwho did not stand for election, and Stig Strobaekwho has not been re-elected, will resign.
About Employee-Elected Board Members
According to Danish company law, employees of Novo Nordisk A/S are entitled to be represented by half of the total number of directors elected by the shareholders. The directors elected by the employees have a statutory mandate of four years and have the same rights, duties and responsibilities as the directors elected by the shareholders.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our goal is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do this by paving the way for scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 47,800 people in 80 countries and markets its products in approximately 170 countries. Novo Nordisk B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Mette Kruse Danielsen
Phone. : +45 3079 3883
Phone. : +1 609 664 7308
(C) 2022 electronic news edition, source ENP Newswire